- Home
- COEP vs ANTX Comparison
COEP vs ANTX Comparison
Compare COEP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ANTX
- Stock Information
- Founded
- COEP 2017
- ANTX 2017
- Country
- COEP United States
- ANTX United States
- Employees
- COEP N/A
- ANTX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ANTX Health Care
- Exchange
- COEP Nasdaq
- ANTX Nasdaq
- Market Cap
- COEP 32.4M
- ANTX 37.6M
- IPO Year
- COEP N/A
- ANTX 2022
- Fundamental
- Price
- COEP $10.52
- ANTX $1.13
- Analyst Decision
- COEP
- ANTX Hold
- Analyst Count
- COEP 0
- ANTX 5
- Target Price
- COEP N/A
- ANTX $3.50
- AVG Volume (30 Days)
- COEP 109.2K
- ANTX 149.8K
- Earning Date
- COEP 03-25-2025
- ANTX 03-27-2025
- Dividend Yield
- COEP N/A
- ANTX N/A
- EPS Growth
- COEP N/A
- ANTX N/A
- EPS
- COEP N/A
- ANTX N/A
- Revenue
- COEP N/A
- ANTX N/A
- Revenue This Year
- COEP N/A
- ANTX N/A
- Revenue Next Year
- COEP N/A
- ANTX N/A
- P/E Ratio
- COEP N/A
- ANTX N/A
- Revenue Growth
- COEP N/A
- ANTX N/A
- 52 Week Low
- COEP $2.31
- ANTX $0.87
- 52 Week High
- COEP $13.70
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- COEP 48.65
- ANTX 44.20
- Support Level
- COEP $9.27
- ANTX $1.09
- Resistance Level
- COEP $12.95
- ANTX $1.20
- Average True Range (ATR)
- COEP 1.59
- ANTX 0.05
- MACD
- COEP -0.33
- ANTX 0.01
- Stochastic Oscillator
- COEP 38.56
- ANTX 52.98
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.